SurModics expands with Brookwood buy:
This article was originally published in Clinica
Drug delivery technology provider SurModics has acquired Brookwood Pharmaceuticals, a subsidiary of the Southern Research Institute, for $40m in cash. The deal, which could rise by a further $22m pending the achievement of specific milestones, sees SurModics (Eden Prairie, Minnesota) gain proprietary polymer-based technologies and broaden its range of markets to include oncology, ophthalmology and orthopaedics. Brookwood, which will retain its operating facilities in Birmingham, Alabama, recorded $12.7m in revenues in 2006, and is profitable and cash flow positive, so is expected to be accretive to SurModics' fiscal 2008 earnings.
You may also be interested in...
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.
Theradaptive's “paint-like” regenerative therapeutic can be applied to any device to promote bone regrowth or regenerate tissue.